The skin around the eye is the thinnest on the body — roughly 0.3 to 0.5 mm, with a fraction of the sebaceous and sweat glands found on the cheeks. It shows age five to ten years ahead of the rest of the face, and it is the single most under-served zone in most brand portfolios. Founders will spend eighteen months perfecting a serum and then launch an eye cream that is simply that serum in a smaller jar. That is a mistake. Eye care has its own actives, its own pH and safety envelope, and — in the US, EU, UK and Australia — its own claim and testing expectations. This guide walks the whole path: type the problem, pick the actives, build the four layers, run the right safety tests, clear the regulations, and get the copy right for Amazon and Shopify.

Step 1 — Type the problem: dark circles, puffiness and lines

Evidence-based eye care starts with classification, not with ingredients. A blue-purple under-eye and a brown one are two completely different problems, and no single cream fixes both.

Type	How it looks	What causes it	Ingredient direction	Evidence level
Vascular	Blue-purple, worse in the morning, worse after poor sleep	Dilated or sluggish capillary network, thin overlying skin showing blood	Caffeine, hesperidin/chalcone, vitamin K oxide, gentle massage	Moderate — short-term human data, mostly hours to days
Pigmented	Brown, often symmetric, worse with sun exposure and rubbing	Melanin deposited in the dermis and epidermis	Niacinamide, 3-O-ethyl ascorbic acid, tranexamic acid, alpha-arbutin	Moderate to high — the brightening pathway is well characterized
Structural	A shadow cast by a tear-trough hollow; changes with light angle	Volume loss in the periorbital fat and bone structure	Nothing topical fills a hollow; refer to a clinician	Not applicable

The honest boundary matters commercially as much as it does scientifically: a structural shadow is a shadow, not a color. No topical ingredient fills a tear-trough defect. If a competitor is claiming "erases under-eye hollows in 7 days", that is not a benchmark to match — it is a claim that will attract a National Advertising Division (NAD) challenge or an Amazon listing takedown. In the US, claims are policed after they run, which means the cheapest possible compliance strategy is simply to stop writing claims that cannot be defended.

Puffiness and lines: sort what topicals can actually fix

The second discipline is knowing when to say "this is not a cosmetic problem". Brands that oversell here get returns, not loyalty.

Type	Hallmarks	Can a topical help?
Fluid puffiness	Swollen on waking, settles by mid-afternoon	Yes — caffeine plus a tightening film-former gives visible, short-lived improvement
Fat-pad puffiness	Hereditary, constant, a genuine bulge of orbital fat	No — this is a surgical presentation
Laxity puffiness	Skin sags as it loses elasticity	Partially — signal peptides and low-dose retinaldehyde may firm the appearance over 8 to 12 weeks
Dehydration lines	Fine, crêpey, disappear once moisturized	Yes — sodium hyaluronate plus ceramides, fast response
Expression lines	Crow's feet that appear when smiling	Yes — acetyl hexapeptide-8 is the standard tool
Static wrinkles	Visible at rest	Partially — low-dose retinaldehyde, proxylane, and collagen-supporting peptides; results are slow and modest

Build the line around one primary complaint. The eye care aisle rewards clarity: a "de-puffing eye gel for morning faces" outsells an "all-in-one eye miracle" at the same price, every time.

Step 2 — The three actives with real evidence behind them

I do not chase every quarter's new launch. Three ingredient families carry the category, and each has a working concentration range that actually matters on the label.

Active	Mechanism	Working level	Evidence level	Best paired with
Caffeine	Vasoconstriction and improved microcirculation; also a mild diuretic effect on local fluid	1% – 3%	Moderate — solid short-term de-puffing data, thin long-term data on stubborn pigmentation	Hesperidin, vitamin K oxide, a cooling applicator
Acetyl Hexapeptide-8	Mimics a SNAP-25 fragment and dampens neurotransmitter release, softening expression-muscle contraction	5% – 10% as supplied (typically a 0.05% – 0.1% peptide solution)	Moderate to high — human studies show reduced wrinkle depth over 4 to 8 weeks	Palmitoyl pentapeptide-4, sodium hyaluronate
Recombinant collagen (Type III / Type I)	Humectant film, barrier support, signals associated with collagen expression	0.5% – 3% depending on grade	Moderate to high for hydration and repair; anti-wrinkle data relies on human use studies and industry consensus	Ceramides, proxylane, panthenol

Add ceramides at 0.1% – 1% as the base of every eye formula. Periorbital skin is barrier-poor by design; repair first, efficacy second. Skipping the safety layer is how a product earns one-star reviews that say "burned my eyes".

A note on concentrations: peptide raw materials are sold as dilute solutions. "10% acetyl hexapeptide-8" on a formula sheet almost always means 10% of a solution containing a fraction of a percent of actual peptide. When you compare supplier quotes, always ask for the active peptide content on the COA, not the solution inclusion rate. This single question separates serious buyers from the ones who get reformulated six months later.

Step 3 — The four-layer framework for eye cream and eye patches

A good formula is a structure, not a shopping list. Four layers have to be present in both formats.

Layer	Job	Eye cream	Eye patches
Efficacy layer	Addresses the primary complaint	Caffeine 1–3% for puffiness; acetyl hexapeptide-8 for expression lines; retinaldehyde 0.02–0.05% for static lines	Same actives at slightly higher levels; a patch is a 15-minute occlusion event, so tolerance is a little better than leave-on
Booster layer	Makes the actives work	Sodium hyaluronate, panthenol, glycerin; add niacinamide 2–4% for the pigmented type	Essence load: 1.5–3.0 g per patch is the practical band; below that the patch dries out before it works
Sensory layer	Drives repeat purchase	Light gel for day and oily skin, richer cream for night and dry skin; metal or ceramic applicator for the cooling cue	Cut that follows the orbital bone, no drip, no rinse needed
Safety layer	Protects the review score	Low-irritant preservative system, pH 5.0–6.5, fragrance-free or very low fragrance, no high-dose acids	Same, plus a full eye-area irritation test — always

Compatibility rules that are non-negotiable

Avoid high-strength L-ascorbic acid, retinaldehyde above 0.1%, and glycolic or lactic acid above 5% in leave-on eye products. The periorbital irritation threshold is far lower than the cheek's.
If fragrance sits in the first ten positions of the INCI list on an eye product, reject it outright.
Caffeine plus peptides plus ceramides is a safe, boring, effective combination. Boring sells refills.
Retinaldehyde plus niacinamide is synergistic, but patch-test it on sensitive panels before you commit to a launch date.

Step 4 — Eye-area safety testing: what to run before you claim anything

This is where the US, EU, UK and Australian expectations converge, and where most first-time brands under-budget. A face cream test package is not sufficient for a product that sits millimetres from a mucous membrane.

Test	What it answers	Typical read-out time	Budget planning range (USD)
In vitro eye irritation — OECD TG 492 (reconstructed human cornea-like epithelium), TG 437 (BCOP) or TG 438 (isolated chicken eye)	Is the formula an eye irritant under GHS classification?	1–2 weeks	$800 – $2,500
HET-CAM (hen's egg chorioallantoic membrane)	Vascular tolerance screen, widely used for eye-area cosmetics	Under 1 week	$300 – $1,200
HRIPT (human repeat insult patch test, 100–200 panelists)	Irritation and sensitization on human skin	6–8 weeks	$5,000 – $15,000
Ophthalmologist-supervised 4-week use test	Supports "ophthalmologist-tested" and "suitable for contact lens wearers"	6–10 weeks	$6,000 – $18,000
Preservative efficacy test (ISO 11930)	Confirms the preservative system survives the packaging and the consumer	6 weeks	$1,000 – $3,000
Stability and packaging compatibility (3 months at 40°C/75% RH plus freeze-thaw)	Shelf life and pack interaction	12–14 weeks elapsed	$1,500 – $4,000

These are industry planning ranges, not quotations; your laboratory, panel size and market will move them. The point is sequencing: run the in vitro eye screen during sampling, not after you have printed 10,000 units.

Two framing rules follow from the testing. If the only evidence you hold is a supplier brochure, you may say "formulated with caffeine" and "helps reduce the look of puffiness" — appearance-level, consumer-perceptible language. You may not say "clinically proven to eliminate eye bags". As Dr. Dray puts it on the record: "When a brand says 'clinically tested', that tells you almost nothing." She is right, and the reason is that "clinically tested" is silent about who, how many, against what, and with what result. If you want the word "clinically" on your packaging, commission a study with a defined endpoint and a defined panel, then write the result honestly: "in a 4-week study of 42 participants, 81% said under-eye puffiness looked reduced."

Step 5 — The regulatory checklist before a single unit ships

The US operates a post-market, self-substantiating system. The EU operates a pre-notification system with an enormous prohibited list. Brands selling across both have to run two playbooks at once.

Requirement	United States (MoCRA)	European Union (1223/2009)	United Kingdom	Australia
Who is accountable	The "Responsible Person" — the brand whose name is on the label; the obligation to hold safety substantiation sits here, not with the contract manufacturer	An EU Responsible Person established in the EU, holding the Product Information File	A UK Responsible Person, with notification to OPSS via the SCPN portal	The Australian sponsor/importer; ingredient introductions are governed by AICIS
Pre-market step	No approval. Facility registration and product listing after market entry; renewal of listing annually and of registration every two years	CPNP notification before placing on market, plus a signed Cosmetic Product Safety Report	Submit Cosmetic Product Notification before placing on market	No pre-market approval for most cosmetics, but each industrial chemical must be on the AIIC inventory or covered by an assessment
Facility obligations	Register each manufacturing facility; foreign facilities must appoint a US Agent	Not applicable to the facility itself	Not applicable to the facility itself	Not applicable for cosmetics manufacturing
Prohibited substances	Roughly a dozen substances prohibited or restricted at federal level	More than 1,600 substances prohibited in Annex II, plus restricted and positive lists for colorants, preservatives and UV filters	Mirrors the EU list post-Brexit, maintained separately	Controlled through the poisons schedules and AICIS assessments
Safety evidence	The Responsible Person must ensure adequate substantiation of safety; records must exist before sale	A qualified safety assessor signs the safety report; the PIF is retained for ten years after the last batch	A safety assessment signed by a suitably qualified person; PIF retained	Ingredient-level safety supported by AICIS and, for claims, by Australian Consumer Law
Adverse events	Serious adverse events reported to the FDA within 15 business days; records retained for six years (three for small businesses)	Serious undesirable effects reporting through the responsible person and competent authority	Report to OPSS	Reporting under the consumer goods framework

Three practical consequences. First, name the US Agent in your supply contract and confirm it in writing before the first container ships — a foreign facility without one is not properly registered. Second, do not assume one formula serves all four markets: a preservative or colorant that is routine in the US may simply not be permitted in the EU, which is why most brands run a "banned-and-restricted list" check at formula lock rather than at artwork approval. Third, the small-business carve-out in MoCRA exempts qualifying brands from facility registration and product listing, but it does not exempt them from holding safety substantiation or from following good manufacturing practice. The exemption is administrative, not scientific.

Step 6 — Cost, minimums and timeline in USD

Parameter	Eye cream	Eye patches
Typical MOQ	500 – 1,000 units	500 – 1,000 pieces per run
Sampling	7 – 15 days from a stock formula; 20 – 30 days for a modified base	7 – 15 days from a stock essence; longer if a new mask substrate is being qualified
Mass production	30 – 45 days after sample approval	30 – 45 days
Filled and packed unit cost	Commonly $1.20 – $4.50 depending on active load and pack	Commonly $0.30 – $1.10 per piece
Pack that fits the formula	Airless pump (protects oxidation-prone actives, prevents finger contamination); ceramic or metal applicator tip adds real perceived value	Non-woven, silk, bio-cellulose or hydrogel substrate — pick by essence load and cling, not by price alone
Formula route	Select from the library, tune an existing base, or develop from scratch	Same

Model your landed cost with a customs broker rather than a spreadsheet. Freight, duty rates and tariff treatments on cosmetics moving from China into the US, EU, UK and Australia change on political schedules, and a four-point swing in landed duty can erase the margin on a $6 retail eye cream.

Step 7 — Channel-ready copy for Amazon, Shopify and specialty retail

The same product needs three different vocabularies, and the differences are legal, not cosmetic.

Amazon is the largest single beauty e-commerce channel in the US and the one most likely to remove a listing without warning. Keep the title to the physical facts — format, key active, size, skin type. Move every appearance claim into the bullet points backed by your study. Avoid cure, treat, heal, repair the skin, and any reference to a disease, including "eczema" and "melasma". An SPF claim without a Drug Facts panel turns a cosmetic into an unapproved new drug overnight.
Shopify DTC gives you room for the full evidence story: panel size, duration, instrument used, and what percentage of users noticed what. Brands like The Ordinary built a category on exactly this kind of disclosure, and Paula's Choice built one on explaining the mechanism. Consumers who read INCI lists reward specificity and punish adjectives.
Sephora and Ulta Beauty run ingredient and claim review before listing, and Ulta's Conscious Beauty program has its own restricted-substance and attribute criteria. Everything on the carton has to reconcile with the PIF or the safety report you signed, so get retailer paperwork into the critical path before you set a launch date, not after.
TikTok Shop enforces health-claim rules at the creator level. If your affiliate brief says "gets rid of eye bags", the creator will say it on camera and you will own the problem. Write the brief around the words you have substantiated and forbid the rest in writing.

Step 8 — Three traps that kill eye care launches

Chasing a ten-in-one claim. The shopper who wants de-puffing and the shopper who wants line reduction are different people. Pick one, name it in the product name, and let the search term do the work.
Budgeting for the formula but not the evidence. A $2,000 in vitro eye screen and a $9,000 HRIPT are the difference between a launch and a recall. Put the testing line in the same spreadsheet as the tooling line.
Treating eye patches as a smaller eye cream. Patches are an acquisition product — low price, high shareability, frequent repurchase. The cream is the retention product. Design them as a system: patch for the first-time buyer, cream for the second order.

QuickOEM landing plan

QuickOEM connects global beauty brands with more than 500 vetted Chinese cosmetics factories, and eye care is one of our deepest categories — eye creams, eye serums, and under-eye patches in non-woven, bio-cellulose and hydrogel formats.

MOQ: 500 – 1,000 units per SKU for both eye cream and eye patches, scalable in tiers
Sampling: 7 – 15 days from stock formulas; 20 – 30 days with base modification
Mass production: 30 – 45 days after sample sign-off
Packaging: airless pumps, ceramic or metal applicator tips, hydrogel and bio-cellulose patch substrates, all with compatibility data
Documentation: ISO 22716 (GMP) manufacturing, COA and raw-material traceability, safety assessment support, ISO 11930 preservative efficacy, stability data, and coordination of the in vitro eye irritation and HRIPT panels your market requires

Tell us the single complaint your line is built around — puffiness, dark circles, or lines — and we will match you with factories that already hold the formula, the substrate and the compliance file to support it. Start at www.quickoem.com.

Educational content for brand owners. Efficacy judgements reflect published research and industry consensus; your own formula, concentrations and claims must be confirmed against your safety assessment, your commissioned studies, and the current rules of the market you sell in. Persistent redness, swelling or pigment change around the eye warrants a clinician, not a cream.

Eye Care Formulation Guide: Dark Circles, Puffiness & Lines